Eli Lilly (LLY) Depreciation & Amortization (CF) (2009 - 2026)

Eli Lilly has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $509.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 9.94% year-over-year to $509.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (up 11.69% YoY), and the FY2025 full-year result was $2.0 billion, up 13.02% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $509.0 million, down from $585.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $585.7 million in Q4 2025, with the low at $348.9 million in Q2 2022.
• Historically, Depreciation & Amortization (CF) has averaged $430.7 million across 5 years, with a median of $414.4 million in 2024.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) dropped 16.85% — and 2024, when it climbed 25.25%.
• Eli Lilly's Depreciation & Amortization (CF) stood at $375.0 million in 2022, then increased by 3.31% to $387.4 million in 2023, then gained by 25.25% to $485.2 million in 2024, then increased by 20.71% to $585.7 million in 2025, then dropped by 13.1% to $509.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $509.0 million (Q1 2026), $585.7 million (Q4 2025), and $470.0 million (Q3 2025), per Business Quant data.